KRAS and cancer: It effectively degrades KRAS G12C and disrupts MAPK signal transmission, offering a new strategy for treating cancers driven by KRAS mutations.13 In addition, compound 8o has demonstrated significant efficacy in degrading various KRAS mutants (including G12C, G12V, G12S, G12R, G13D), while sparing wild-type KRAS.